SEC Form 4 · accession 0001209191-15-085975

Anacor Pharmaceuticals, Inc. · ANAC

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP and Chief Medical Officer

Period of report

Dec 15, 2015

Accepted (ET)

Dec 17, 2015 · 9:01 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001411158

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Dec 15, 2015	M	14,000	$5.59	A	42,747	D
Common Stock^F3	Dec 15, 2015	S	1,574	$112.0578	D	41,173	D
Common Stock^F4	Dec 15, 2015	S	9,430	$113.1436	D	31,743	D
Common Stock^F5	Dec 15, 2015	S	2,896	$113.7859	D	28,847	D
Common Stock	Dec 15, 2015	S	100	$114.99	D	28,747	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F6	$5.59	Dec 15, 2015	M	14,000	D	—	Mar 13, 2022	Common Stock	14,000	27,661	D

F1Includes shares purchased in 2015 pursuant to the Issuer's ESPP.
F2This sale was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.55 to $112.54, inclusive.
F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.56 to $113.55, inclusive.
F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.56 to $114.055, inclusive.
F6The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting each month thereafter. The Vesting Commencement Date was January 1, 2012.